Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
CLDX's Cash-to-Debt is ranked higher than
97% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CLDX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CLDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.95  Med: 275.59 Max: No Debt
Current: No Debt
Equity-to-Asset 0.67
CLDX's Equity-to-Asset is ranked higher than
51% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CLDX: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
CLDX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.84 Max: 0.94
Current: 0.67
-0.32
0.94
Interest Coverage No Debt
CLDX's Interest Coverage is ranked higher than
96% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CLDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CLDX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -2.08
Beneish M-Score: -1.10
WACC vs ROIC
18.29%
-237.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1363.00
CLDX's Operating Margin % is ranked lower than
83% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CLDX: -1363.00 )
Ranked among companies with meaningful Operating Margin % only.
CLDX' s Operating Margin % Range Over the Past 10 Years
Min: -3414.11  Med: -878.49 Max: -13.79
Current: -1363
-3414.11
-13.79
Net Margin % -1319.08
CLDX's Net Margin % is ranked lower than
83% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. CLDX: -1319.08 )
Ranked among companies with meaningful Net Margin % only.
CLDX' s Net Margin % Range Over the Past 10 Years
Min: -3292.81  Med: -854.57 Max: -5.41
Current: -1319.08
-3292.81
-5.41
ROE % -52.12
CLDX's ROE % is ranked lower than
59% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CLDX: -52.12 )
Ranked among companies with meaningful ROE % only.
CLDX' s ROE % Range Over the Past 10 Years
Min: -2929.64  Med: -56.47 Max: -3.4
Current: -52.12
-2929.64
-3.4
ROA % -38.67
CLDX's ROA % is ranked lower than
59% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CLDX: -38.67 )
Ranked among companies with meaningful ROA % only.
CLDX' s ROA % Range Over the Past 10 Years
Min: -120  Med: -41.12 Max: -2.02
Current: -38.67
-120
-2.02
ROC (Joel Greenblatt) % -1068.34
CLDX's ROC (Joel Greenblatt) % is ranked lower than
62% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. CLDX: -1068.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CLDX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1193.97  Med: -658.84 Max: -10.72
Current: -1068.34
-1193.97
-10.72
3-Year Revenue Growth Rate 8.80
CLDX's 3-Year Revenue Growth Rate is ranked higher than
59% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CLDX: 8.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CLDX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -67.2  Med: -23.5 Max: 105.6
Current: 8.8
-67.2
105.6
3-Year EBITDA Growth Rate 9.20
CLDX's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CLDX: 9.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CLDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -32.2  Med: -2.1 Max: 53.7
Current: 9.2
-32.2
53.7
3-Year EPS without NRI Growth Rate 7.60
CLDX's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CLDX: 7.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CLDX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64.6  Med: 1.4 Max: 163.4
Current: 7.6
-64.6
163.4
GuruFocus has detected 3 Warning Signs with Celldex Therapeutics Inc $CLDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CLDX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CLDX Guru Trades in Q3 2016

Jim Simons 1,258,214 sh (+61.97%)
First Eagle Investment 445,000 sh (unchged)
Murray Stahl 26,335 sh (unchged)
John Paulson 70,800 sh (unchged)
Paul Tudor Jones 13,406 sh (-11.44%)
Columbia Wanger 2,907,523 sh (-44.74%)
» More
Q4 2016

CLDX Guru Trades in Q4 2016

Paul Tudor Jones 47,806 sh (+256.60%)
Columbia Wanger 6,195,855 sh (+113.10%)
John Paulson 70,800 sh (unchged)
Murray Stahl 26,335 sh (unchged)
First Eagle Investment Sold Out
Jim Simons 1,199,710 sh (-4.65%)
» More
Q1 2017

CLDX Guru Trades in Q1 2017

Jim Simons 1,707,927 sh (+42.36%)
Murray Stahl 26,335 sh (unchged)
John Paulson Sold Out
Paul Tudor Jones Sold Out
Columbia Wanger 6,019,590 sh (-2.84%)
» More
Q2 2017

CLDX Guru Trades in Q2 2017

Paul Tudor Jones 14,499 sh (New)
Columbia Wanger 8,526,619 sh (+41.65%)
Murray Stahl 26,335 sh (unchged)
Jim Simons 348,614 sh (-79.59%)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-03-31 Sold Out $3.17 - $3.96 $ 3.00-14%0
First Eagle Investment 2016-12-31 Sold Out $2.87 - $4.92 $ 3.00-21%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2835
Compare:NAS:NVAX, NAS:CRVS, NAS:GERN, NAS:CRBP, NAS:IDRA, NAS:CCXI, NAS:BSTC, NAS:RARX, NAS:CBAY, AMEX:BTX, OTCPK:AXIM, NAS:NLNK, NAS:CNCE, NAS:BLCM, NAS:SYBX, NAS:CORI, NAS:EDGE, NAS:NERV, NAS:SYRS, NAS:ATHX » details
Traded in other countries:TCE1.Germany,
Headquarter Location:USA
Celldex Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

Celldex Therapeutics Inc was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidates are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of protein-based molecules such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. Its stage drug candidate, Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as EGFRvIII. Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate in a randomized, Phase 2b study for the treatment of triple negative breast cancer and a Phase 2 study for the treatment of metastatic melanoma. Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient's immune response against their cancer. It established proof of concept in a Phase 1 study with varlilumab, which has allowed several combination studies to begin in various indications. The Company is a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. Its clinical development programs include Rintega, Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, CDX-014. The Company relies on contract manufacturing organizations, or CMOs, to manufacture drug substance and drug product for its late-stage clinical studies of Rintega and glembatumumab vedotin as well as for future commercial supplies. It also relies on CMOs for filling and packaging, labeling, storage and shipping of drug product. The Company own or license rights under more than 300 granted patents and national and regional patent applications in the U.S. and in international territories covering inventions relating to its business. Competitors that the Company is aware of that have initiated a Phase 3 study or have obtained marketing approval for a potential competitive drug/device for Rintega in the treatment of glioblastoma and/or glembatumumab vedotin in the treatment of breast cancer include AbbVie, Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Bristol-Myers Squibb, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Novartis, Novocure, Pfizer Inc., and Roche.

Ratios

vs
industry
vs
history
PB Ratio 1.77
CLDX's PB Ratio is ranked higher than
89% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CLDX: 1.77 )
Ranked among companies with meaningful PB Ratio only.
CLDX' s PB Ratio Range Over the Past 10 Years
Min: 1.23  Med: 4.37 Max: 50.74
Current: 1.77
1.23
50.74
PS Ratio 39.08
CLDX's PS Ratio is ranked lower than
73% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CLDX: 39.08 )
Ranked among companies with meaningful PS Ratio only.
CLDX' s PS Ratio Range Over the Past 10 Years
Min: 1.68  Med: 47.6 Max: 1014.4
Current: 39.08
1.68
1014.4
EV-to-EBIT -2.02
CLDX's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CLDX: -2.02 )
Ranked among companies with meaningful EV-to-EBIT only.
CLDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -77.2  Med: -3.7 Max: 0.3
Current: -2.02
-77.2
0.3
EV-to-EBITDA -2.10
CLDX's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CLDX: -2.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -515.4  Med: -3.4 Max: 39.2
Current: -2.1
-515.4
39.2
EV-to-Revenue 27.74
CLDX's EV-to-Revenue is ranked lower than
61% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CLDX: 27.74 )
Ranked among companies with meaningful EV-to-Revenue only.
CLDX' s EV-to-Revenue Range Over the Past 10 Years
Min: -6  Med: 28.5 Max: 941.6
Current: 27.74
-6
941.6
Current Ratio 5.56
CLDX's Current Ratio is ranked higher than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CLDX: 5.56 )
Ranked among companies with meaningful Current Ratio only.
CLDX' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.48 Max: 17.22
Current: 5.56
0.56
17.22
Quick Ratio 5.56
CLDX's Quick Ratio is ranked higher than
66% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CLDX: 5.56 )
Ranked among companies with meaningful Quick Ratio only.
CLDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.41 Max: 17.22
Current: 5.56
0.56
17.22
Days Sales Outstanding 52.46
CLDX's Days Sales Outstanding is ranked lower than
54% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CLDX: 52.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.43  Med: 38.85 Max: 95.96
Current: 52.46
1.43
95.96

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.50
CLDX's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CLDX: -10.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -73.1  Med: -15.9 Max: 0
Current: -10.5
-73.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.68
CLDX's Price-to-Net-Cash is ranked higher than
61% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. CLDX: 9.68 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CLDX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.76  Med: 6.64 Max: 47.3
Current: 9.68
1.76
47.3
Price-to-Net-Current-Asset-Value 8.33
CLDX's Price-to-Net-Current-Asset-Value is ranked higher than
62% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CLDX: 8.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CLDX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.7  Med: 6.27 Max: 1163
Current: 8.33
1.7
1163
Price-to-Tangible-Book 6.38
CLDX's Price-to-Tangible-Book is ranked higher than
57% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CLDX: 6.38 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CLDX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.62  Med: 5.02 Max: 54.69
Current: 6.38
1.62
54.69
Price-to-Median-PS-Value 0.76
CLDX's Price-to-Median-PS-Value is ranked higher than
65% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CLDX: 0.76 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CLDX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.51 Max: 26.21
Current: 0.76
0.04
26.21
Earnings Yield (Greenblatt) % -49.26
CLDX's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CLDX: -49.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CLDX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2086  Med: -26.6 Max: 3208.4
Current: -49.26
-2086
3208.4

More Statistics

Revenue (TTM) (Mil) $9.46
EPS (TTM) $ -1.10
Beta2.67
Short Percentage of Float12.52%
52-Week Range $2.20 - 5.02
Shares Outstanding (Mil)128.34

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 9 6 6 65
EPS ($) -1.05 -1.06 -1.05 -0.91
EPS without NRI ($) -1.05 -1.06 -1.05 -0.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}